scholarly journals Uromodulin as a potential candidate marker for predicting the course of chronic kidney disease

KIDNEYS ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 237-243
Author(s):  
L.D. Denova
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Kidney Stones ◽  
Autosomal Dominant ◽  
Gene Mutations ◽  
Potential Candidate ◽  
Candidate Marker ◽  
Daily Excretion ◽  
Normal Urine ◽  
Tract Infections

Uromodulin is a nephrospecific protein that is most common in normal urine. And although it has been known for more than 70 years, the function of uromodulin remains unclear. Uromodulin is involved in regulating the transport of salts, protects against urinary tract infections, namely, the mucous membrane of the bladder, and prevents the formation of kidney stones, as well as plays a role in kidney damage and innate immunity. Serum uromodulin and uromodulin of urine, daily excretion and excretion of uromodulin per 1 milliliter of creatinine clearance are actively studied. Complete genome studies of the association have established a correlation between uromodulin gene mutations and autosomal dominant tubulointerstitial kidney disease.

scholarly journals Vasopressin Induces Urinary Uromodulin Secretion By Activating PKA (Protein Kinase A)

Hypertension ◽  
2021 ◽  
Author(s):  
Azuma Nanamatsu ◽  
Takayasu Mori ◽  
Fumiaki Ando ◽  
Taisuke Furusho ◽  
Shintaro Mandai ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Urinary Tract ◽  
Protein Kinase ◽  
Kidney Disease ◽  
Protein Kinase A ◽  
Urinary Tract Infections ◽  
Kidney Stones ◽  
Camp Signaling ◽  
Tract Infections ◽  
Kinase A

Urinary uromodulin, secreted by renal tubular cells, protects against urinary tract infections and kidney stones. In contrast, the intracellular accumulation of uromodulin is associated with hypertension and chronic kidney disease. However, the physiological stimuli for urinary uromodulin secretion remain largely unknown. Here, we showed that desmopressin, a vasopressin type 2 receptor agonist, dramatically increased short-term tubular uromodulin secretion in mice. Immunofluorescence studies and ultracentrifugation-based polymerization assay suggested that desmopressin induced intraluminal polymeric filaments of uromodulin, indicating physiologically functional secretion. As a result of increased excretion, uromodulin abundance in the murine kidney was clearly reduced by desmopressin. We investigated kidney epithelial cells stably expressing uromodulin to clarify the molecular mechanism. Apical uromodulin secretion was clearly increased in response to vasopressin/cAMP signaling, consistent with in vivo experiments. We also demonstrated that the response was dependent on epithelial cell polarity and cyclic AMP-dependent PKA (protein kinase A) signaling pathway. cAMP-mediated activation of proteases was suggested to be involved. In contrast, basolateral secretion of uromodulin was independent of cAMP signaling. Our work revealed vasopressin/cAMP/PKA signaling as a physiological stimulus of urinary uromodulin secretion. This finding may provide the basis for novel treatment strategies for urinary tract infections, kidney stones, and potentially hypertension and chronic kidney disease.

Hyperuricemia and Cardiovascular Disease

2019 ◽  
Vol 25 (6) ◽  
pp. 700-709 ◽  
Author(s):  
Shuangshuang Zhang ◽  
Yong Wang ◽  
Jinsong Cheng ◽  
Ning Huangfu ◽  
Ruochi Zhao ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Chronic Kidney Disease ◽  
Uric Acid ◽  
Kidney Disease ◽  
Kidney Stones ◽  
Treatment Plan ◽  
Circulatory System ◽  
Special Focus ◽  
Positive Effects

Purine metabolism in the circulatory system yields uric acid as its final oxidation product, which is believed to be linked to the development of gout and kidney stones. Hyperuricemia is closely correlated with cardiovascular disease, metabolic syndrome, and chronic kidney disease, as attested by the epidemiological and empirical research. In this review, we summarize the recent knowledge about hyperuricemia, with a special focus on its physiology, epidemiology, and correlation with cardiovascular disease. This review also discusses the possible positive effects of treatment to reduce urate levels in patients with cardiovascular disease and hyperuricemia, which may lead to an improved clinical treatment plan.

scholarly journals Risk of Hospital Encounters With Kidney Stones in Autosomal Dominant Polycystic Kidney Disease: A Cohort Study

2021 ◽  
Vol 8 ◽  
pp. 205435812110002
Author(s):  
Vinusha Kalatharan ◽  
Blayne Welk ◽  
Danielle M. Nash ◽  
Stephanie N. Dixon ◽  
Justin Slater ◽  
...  
Keyword(s):  
Cohort Study ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Kidney Stones ◽  
Autosomal Dominant ◽  
Significant Risk ◽  
Hazard Ratio ◽  
Cox Proportional Hazards Model ◽  
Polycystic Kidney ◽  
Autosomal Dominant Polycystic Kidney

Background: There is a perception that patients with autosomal dominant polycystic kidney disease (ADPKD) are more likely to develop kidney stones than the general population. Objective: To compare the rate of hospital encounter with kidney stones and the rate of stone interventions between patients with and without ADPKD. Design: Retrospective cohort study. Setting: Ontario, Canada. Patients: Patients with and without ADPKD who had a prior hospital encounter between 2002 and 2016. Measurements: Rate of hospital encounter with kidney stones and rate of stone intervention. Methods: We used inverse probability exposure weighting based on propensity scores to balance baseline indicators of health between patients with and without ADPKD. We followed each patient until death, emigration, outcomes, or March 31, 2017. We used a Cox proportional hazards model to compare event rates between the two groups. Results: Patients with ADPKD were at higher risk of hospital encounter with stones compared with patients without ADPKD (81 patients of 2094 with ADPKD [3.8%] vs 60 patients of 1902 without ADPKD [3.2%]; 8.9 vs 5.1 events per 1000 person-years; hazard ratio 1.6 [95% CI, 1.3-2.1]). ADPKD was not associated with a higher risk of stone intervention (49 of 2094 [2.3%] vs 47 of 1902 [2.4%]; 5.3 vs 3.9 events per 1000 person-years; hazard ratio 1.2 [95% CI = 0.9-1.3]). Limitations: We did not have information on kidney stone events outside of the hospital. There is a possibility of residual confounding. Conclusion: ADPKD was a significant risk factor for hospital encounters with kidney stones.

P318 The nexus between chronic kidney disease and urinary tract infections

2017 ◽  
Author(s):  
Teofana Otilia Bizerea ◽  
Anca Roxana Paul ◽  
Ramona Stroescu ◽  
Raluca Isac ◽  
Mihai Gafencu ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Urinary Tract ◽  
Kidney Disease ◽  
Urinary Tract Infections ◽  
Tract Infections

scholarly journals History of kidney stones and risk of chronic kidney disease: a meta-analysis

PeerJ ◽  
2017 ◽  
Vol 5 ◽  
pp. e2907 ◽  
Author(s):  
Weifeng Shang ◽  
Lixi Li ◽  
Yali Ren ◽  
Qiangqiang Ge ◽  
Ming Ku ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Kidney Stones ◽  
Meta Analysis ◽  
Positive Association ◽  
Significant Heterogeneity ◽  
Adjusted Risk ◽  
Increased Risk ◽  
Subgroup Analyses ◽  
History Of

Background Although the relationship between a history of kidney stones and chronic kidney disease (CKD) has been explored in many studies, it is still far from being well understood. Thus, we conducted a meta-analysis of studies comparing rates of CKD in patients with a history of kidney stones. Methods PubMed, EMBASE, and the reference lists of relevant articles were searched to identify observational studies related to the topic. A random-effects model was used to combine the study-specific risk estimates. We explored the potential heterogeneity by subgroup analyses and meta-regression analyses. Results Seven studies were included in this meta-analysis. Pooled results suggested that a history of kidney stones was associated with an increased adjusted risk estimate for CKD [risk ratio (RR), 1.47 95% confidence interval (CI) [1.23–1.76])], with significant heterogeneity among these studies (I2 = 93.6%, P < 0.001). The observed positive association was observed in most of the subgroup analyses, whereas the association was not significant among studies from Asian countries, the mean age ≥50 years and male patients. Conclusion A history of kidney stones is associated with increased risk of CKD. Future investigations are encouraged to reveal the underlying mechanisms in the connection between kidney stones and CKD, which may point the way to more effective preventive and therapeutic measures.

Flexible Ureterorenoscopy Is Safe and Efficient for the Treatment of Kidney Stones in Patients With Chronic Kidney Disease

Urology ◽  
2014 ◽  
Vol 84 (6) ◽  
pp. 1279-1284 ◽  
Author(s):  
Emrah Yuruk ◽  
Murat Binbay ◽  
Faruk Ozgor ◽  
Akif Erbin ◽  
Yalcin Berberoglu ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Kidney Stones ◽  
Flexible Ureterorenoscopy

Plant-Based Milk Alternatives and Risk Factors for Kidney Stones and Chronic Kidney Disease

2021 ◽  
Author(s):  
James F. Borin ◽  
John Knight ◽  
Ross P. Holmes ◽  
Shivam Joshi ◽  
David S. Goldfarb ◽  
...  
Keyword(s):  
Risk Factors ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Kidney Stones

Risk Factors for Chronic Kidney Disease

2019 ◽  
pp. 29-38
Author(s):  
Hania Kassem ◽  
Bernard G. Jaar
Keyword(s):  
Risk Factors ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Kidney Stones ◽  
Developed Countries ◽  
Modifiable Risk Factors ◽  
Public Health Burden ◽  
Obstructive Sleep ◽  
Significant Public Health ◽  
Common Risk Factors

Chronic kidney disease (CKD) represents a significant public health burden worldwide and several risk factors have been identified over the years; these have been well-described in the medical literature. Common risk factors such as diabetes mellitus and hypertension will be described in other chapters. While this chapter will focus mainly on CKD risk factors observed in developed countries, several of these are also observed in developing countries. It is now well-established that some risk factors are modifiable while others are non-modifiable. In this chapter, we will explore several of these non-modifiable risk factors in more detail, such as age, gender, race, family history, and low birth weight. But we will also discuss some of the modifiable risk factors such as kidney stones, obstructive sleep apnea, smoking, drugs (excluding NSAIDs), diet, obesity, metabolic syndrome, and hyperuricemia. We will provide a balanced and up to date review of the evidence linking these risk factors with CKD.

Sign in / Sign up

Export Citation Format

Share Document